Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.

Date publication

avril 2017

Journal

Acta oncologica (Stockholm, Sweden)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COLLIN Françoise

Tous les auteurs :
Young RJ, Litière S, Lia M, Hogendoorn PCW, Fisher C, Mechtersheimer G, Daugaard S, Sciot R, Collin F, Messiou C, Grünwald V, Gronchi A, van der Graaf W, Wardelmann E, Judson I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28431480

Résumé

The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma (STS). Analysis of the main study showed that combination chemotherapy improved tumor response and progression-free survival, but differences in overall survival (OS) were not statistically significant. We analyzed factors prognostic for tumor response and OS, and assessed histological subgroup and tumor grade as predictive factors to identify patients more likely to benefit from combination chemotherapy.

Mots clés

Adult, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bone Neoplasms, drug therapy, Doxorubicin, administration & dosage, Female, Follow-Up Studies, Humans, Ifosfamide, administration & dosage, Liver Neoplasms, drug therapy, Lung Neoplasms, drug therapy, Lymphatic Metastasis, Male, Middle Aged, Prognosis, Prospective Studies, Sarcoma, drug therapy, Survival Rate

Référence

Acta Oncol. 2017 Apr;:1-8